TRT for Fatigue: Does Testosterone Replacement Actually Work?

What Is the Link Between Low Testosterone and Fatigue?

Testosterone drives mitochondrial energy production, red blood cell synthesis, and central dopaminergic tone. When serum levels fall, men often report a persistent, non-restorative tiredness that sleep does not fix. The European Male Aging Study (N=3,369) found that three sexual symptoms combined with a total testosterone below 320 ng/dL defined late-onset hypogonadism, with fatigue and low energy among the most reported non-sexual complaints [1].

Testosterone acts on androgen receptors in skeletal muscle, the hypothalamus, and erythroid progenitor cells. Low T reduces erythropoietin sensitivity, which can lower hemoglobin by 1 to 2 g/dL, enough to produce exertional fatigue even without frank anemia [2]. Separately, testosterone modulates dopamine receptor density in the mesolimbic pathway, which is why hypogonadal men frequently describe motivational fatigue alongside physical tiredness [3].

The 2018 American Urological Association (AUA) guideline states: "Testosterone deficiency is a well-established, recognized medical condition that negatively affects male sexuality, reproduction, general health, and quality of life." [4] Fatigue is explicitly listed as a symptom warranting evaluation.

Not every tired man has low testosterone. Thyroid dysfunction, sleep apnea, iron deficiency, and depression each produce similar symptoms. A proper workup rules these out before TRT is initiated [5].

Primary vs. Secondary Hypogonadism: Why the Distinction Matters for Treatment

The cause of low testosterone determines treatment strategy. Primary hypogonadism originates in the testes themselves. Secondary hypogonadism originates in the pituitary or hypothalamus.

In primary hypogonadism, the testes fail to produce adequate testosterone despite normal or high signaling from above. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are elevated because the pituitary is compensating. Causes include Klinefelter syndrome, orchitis, chemotherapy, and radiation [6]. TRT is the standard treatment because the problem is end-organ failure.

Secondary hypogonadism shows low or inappropriately normal LH and FSH alongside low testosterone. Causes include hyperprolactinemia, hypothalamic suppression from obesity, opioid use, or pituitary adenoma [7]. In secondary cases, the pituitary still has potential. Clomiphene citrate 25 to 50 mg daily or human chorionic gonadotropin (hCG) can stimulate endogenous production, preserving fertility, an option TRT eliminates by suppressing gonadotropins [8].

The 2018 Endocrine Society guideline recommends measuring LH, FSH, and prolactin in all men with confirmed hypogonadism to classify the type before prescribing [9]. Skipping this step risks missing a pituitary adenoma that needs MRI and separate treatment.

A practical classification framework used by the HealthRX medical team:

1. Total testosterone <300 ng/dL on two morning samples, confirmed.
2. LH and FSH measured to separate primary from secondary.
3. If secondary: prolactin, MRI of the sella turcica if prolactin >20 ng/mL.
4. If fertility is desired: clomiphene or hCG preferred over TRT.
5. If primary or fertility is not a concern: TRT initiated with the appropriate delivery method.

What the Clinical Trials Show About TRT and Fatigue

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials conducted at 12 U.S. academic medical centers (N=790 men aged 65 and older, total testosterone <275 ng/dL), provide the highest-quality evidence [10]. The Physical Function Trial within TTrials found that testosterone significantly increased 6-minute walk distance and self-reported energy compared to placebo [11].

The Sexual Function Trial (part of TTrials) showed that testosterone treatment improved sexual desire, erectile function, and satisfaction scores versus placebo, with a mean improvement of 2.6 points on the IIEF-sexual desire domain [12].

A 2016 meta-analysis in the Journal of Clinical Endocrinology and Metabolism pooled 35 randomized trials and found that TRT produced statistically significant improvements in fatigue, mood, and sexual function in hypogonadal men [13]. Effect sizes were larger in men with baseline testosterone below 230 ng/dL.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was designed primarily to evaluate cardiovascular safety of testosterone replacement in middle-aged hypogonadal men with high cardiovascular risk. It found no increase in major adverse cardiac events compared to placebo over a median 33 months of follow-up, addressing a long-standing safety concern [14]. Energy and fatigue were secondary endpoints showing modest but consistent benefit in the treated group.

A 2014 Cochrane systematic review of 64 trials concluded that TRT improved sexual function and quality-of-life measures, including energy, but that evidence for bone density and cardiovascular outcomes required longer studies [15].

Andropause and Late-Onset Hypogonadism: Fatigue in Aging Men

Andropause is not a discrete event like menopause. Testosterone declines gradually from age 30 onward at roughly 1 to 2% per year [16]. By age 70, total testosterone averages around 400 ng/dL in healthy men, but free testosterone falls more steeply because sex hormone binding globulin (SHBG) rises with age, binding more of the circulating hormone and leaving less bioavailable [17].

Late-onset hypogonadism (LOH) describes the clinical syndrome that results. The European Male Aging Study placed LOH prevalence at approximately 2.1% in men aged 40, 79, rising to 5.1% in men over 70 [1]. Fatigue is one of the three sexual symptoms required for diagnosis under the EMAS criteria, alongside reduced morning erections and reduced sexual thoughts.

A Lancet Diabetes and Endocrinology analysis of 9,054 men found that the probability of hypogonadism-related symptoms increased sharply once total testosterone fell below 8 nmol/L (approximately 230 ng/dL), but some symptoms such as fatigue appeared at levels up to 11 nmol/L (approximately 317 ng/dL) [18].

Free testosterone measurement is particularly useful in older men. Men over 60 with SHBG above 50 nmol/L may have normal total testosterone but genuinely low free testosterone. Calculated free testosterone below 65 pg/mL is a reasonable secondary diagnostic threshold [9].

TRT for Low Libido: What to Expect

Libido is the symptom most reliably improved by TRT in hypogonadal men. The Testosterone Trials Sexual Function Trial reported that men receiving testosterone gel 1% achieved a mean IIEF-desire score improvement of 1.9 points more than placebo (P<0.001) over 12 months [12].

Free testosterone drives libido more directly than total testosterone. A study in the Journal of Clinical Endocrinology and Metabolism (N=434) found that free testosterone below 5 ng/dL correlated with reduced sexual desire independently of total testosterone levels [19]. This is why calculating or directly measuring free T matters before concluding a man is eugonadal.

Dosing for libido optimization generally targets total testosterone in the 400 to 700 ng/dL range. Levels above 700 ng/dL do not produce further libido gains in most men and increase the risk of erythrocytosis [9]. Estradiol balance also matters: aromatization of testosterone to estradiol supports libido, and overzealous aromatase inhibitor use can reduce sexual desire by crashing estradiol below 20 pg/mL [20].

Expect 4 to 8 weeks before subjective libido improvement. The Endocrine Society guideline notes that sexual symptoms may lag behind serum normalization by several weeks [9].

TRT for Erectile Dysfunction: Realistic Outcomes

Testosterone and erectile function are linked, but erectile dysfunction (ED) has multiple causes and testosterone is only one. TRT alone resolves ED in approximately 57% of hypogonadal men according to a 2014 meta-analysis in the Journal of Sexual Medicine (N=1,473 across 14 trials) [21].

The mechanism is partially vascular. Testosterone maintains nitric oxide synthase activity in penile endothelium, and deficiency reduces corporal smooth muscle relaxation [22]. Low T also reduces nocturnal penile tumescence, which is the physiological mechanism that keeps erectile tissue healthy through daily oxygenation [23].

When TRT alone is insufficient, combining it with a PDE5 inhibitor such as sildenafil 50 to 100 mg or tadalafil 5 mg daily produces additive benefit. A randomized trial published in the Journal of Urology (N=140) found that combination therapy improved IIEF-erectile function domain scores by 6.4 points more than TRT alone in hypogonadal men with residual ED [24].

The AUA erectile dysfunction guideline recommends: "In men with ED and documented testosterone deficiency, testosterone therapy may be considered as initial therapy or as an adjunct to PDE5 inhibitor therapy." [25]

Men with ED but normal testosterone levels should not receive TRT for ED. The evidence does not support using TRT to treat ED in eugonadal men, and the FDA has not approved any testosterone product for this indication [26].

How TRT Is Delivered: Choosing the Right Formulation

FDA-approved testosterone formulations each carry different pharmacokinetics and lifestyle implications [26].

Testosterone cypionate and enanthate injections (intramuscular or subcutaneous, 100 to 200 mg weekly or 50 to 100 mg twice weekly) produce reliable serum levels and are the lowest-cost option. Subcutaneous injection with a 27-gauge, 0.5-inch needle is increasingly preferred for convenience and reduced injection-site pain [9].

Testosterone gels (AndroGel 1%, AndroGel 1.62%, Testim, Vogelxo) are applied daily to shoulders or upper arms. Transference to partners or children through skin contact is a real risk requiring careful handwashing and covering the application site [27].

Testosterone undecanoate (Aveed) is a long-acting injectable administered in a clinic at 0, 4, and then every 10 weeks. It produces stable levels but requires a 30-minute post-injection observation period due to rare pulmonary oil microembolism risk [26].

Natesto nasal gel (11 mg per nostril three times daily) avoids transference risk and causes less suppression of LH than other forms, potentially preserving some testicular function [28].

Subcutaneous pellets (Testopel) are implanted every 3 to 6 months and offer the convenience of no daily or weekly administration, but dose adjustment requires a new insertion procedure.

A 2023 review in the Journal of Clinical Medicine compared delivery methods on the basis of trough stability and patient adherence. Twice-weekly subcutaneous injections and daily gels showed the most consistent trough-to-peak ratios [29].

Monitoring TRT: Labs, Timeline, and Safety

Starting TRT without a follow-up plan exposes men to avoidable risks. The Endocrine Society recommends checking total testosterone, hematocrit, PSA, and a lipid panel at 3 months, 6 months, and annually thereafter [9].

Hematocrit above 54% requires dose reduction or temporary cessation because polycythemia raises thrombosis risk. The TRAVERSE trial found a hematocrit-related adverse event rate of 3.5% in the testosterone arm versus 0.8% in placebo, underscoring the importance of monitoring [14].

PSA should be measured at baseline and at 3 to 6 months. A rise of more than 1.4 ng/mL above baseline within the first year warrants urology referral before continuing TRT [9]. The TRAVERSE trial found no increase in prostate cancer incidence, but surveillance remains standard of care [14].

Bone density (DEXA scan) is recommended at baseline in men with osteopenia or fracture history, repeated at 1 to 2 years [9]. Testosterone increases lumbar spine BMD by roughly 3.7% over 12 months in hypogonadal men according to a 2006 randomized trial in the Annals of Internal Medicine [30].

Expect the following approximate timeline after starting TRT:

• Weeks 1, 3: sleep quality may improve first.
• Weeks 3, 6: fatigue reduction and mood stabilization become noticeable.
• Weeks 6, 12: libido and erectile function improvement.
• Months 3, 6: body composition changes (lean mass up, fat mass down) become measurable.
• Month 12+: bone density gains measurable on DEXA.

Diagnosing Hypogonadism: The Lab Work You Need Before TRT

Fatigue alone does not qualify a man for TRT. The diagnostic minimum requires two morning fasting total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 a.m. [9]. Testosterone follows a circadian rhythm, peaking in the morning and falling 20 to 35% by afternoon; an afternoon draw in a symptomatic man may falsely appear normal [31].

The full initial workup recommended by the 2018 Endocrine Society guideline includes: total testosterone, free or bioavailable testosterone (calculated or dialysis method), LH, FSH, prolactin, CBC, comprehensive metabolic panel, lipid panel, and PSA for men over 40 [9].

Albumin and SHBG are needed to calculate free testosterone using the Vermeulen formula, which is more accurate than most direct immunoassay kits for free T [32]. Lab reference ranges vary; a free testosterone below 65 pg/mL is considered deficient by most endocrinology societies regardless of total T [9].

Thyroid-stimulating hormone (TSH) and ferritin should be checked to exclude hypothyroidism and iron deficiency as concurrent fatigue causes. A 2020 study in BMC Endocrine Disorders found that 18% of men presenting with hypogonadism symptoms had concurrent subclinical hypothyroidism [33].

Sleep apnea screening is appropriate in obese men with fatigue and low T, as untreated obstructive sleep apnea suppresses nocturnal testosterone production by up to 20% [34].